BG108370A - Кристални форми на азитромицин - Google Patents

Кристални форми на азитромицин Download PDF

Info

Publication number
BG108370A
BG108370A BG108370A BG10837003A BG108370A BG 108370 A BG108370 A BG 108370A BG 108370 A BG108370 A BG 108370A BG 10837003 A BG10837003 A BG 10837003A BG 108370 A BG108370 A BG 108370A
Authority
BG
Bulgaria
Prior art keywords
azithromycin
ppm
peaks
crystalline
solid
Prior art date
Application number
BG108370A
Other languages
Bulgarian (bg)
English (en)
Inventor
Zheng Li
Andrew Trask
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG108370(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG108370A publication Critical patent/BG108370A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • A61K9/2826Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BG108370A 2001-05-22 2003-11-18 Кристални форми на азитромицин BG108370A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29256501P 2001-05-22 2001-05-22
US29774101P 2001-06-12 2001-06-12
US34304101P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
BG108370A true BG108370A (bg) 2004-11-30

Family

ID=27404135

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108370A BG108370A (bg) 2001-05-22 2003-11-18 Кристални форми на азитромицин

Country Status (35)

Country Link
US (10) US6977243B2 (sh)
EP (1) EP1390377B1 (sh)
JP (3) JP2004530703A (sh)
KR (1) KR100574153B1 (sh)
AP (1) AP2003002906A0 (sh)
AR (1) AR036022A1 (sh)
AT (2) ATE319730T1 (sh)
AU (1) AU2002256846B2 (sh)
BG (1) BG108370A (sh)
BR (1) BR0209918A (sh)
CA (1) CA2391659C (sh)
CR (1) CR7159A (sh)
CZ (1) CZ20033154A3 (sh)
DE (2) DE60209704T2 (sh)
DK (1) DK1390377T3 (sh)
EA (2) EA009611B1 (sh)
EE (1) EE200300575A (sh)
ES (2) ES2258142T3 (sh)
GE (1) GEP20084399B (sh)
HU (1) HUP0400446A2 (sh)
IL (1) IL158591A0 (sh)
IS (1) IS7007A (sh)
MA (1) MA27023A1 (sh)
MX (1) MXPA03010028A (sh)
MY (1) MY129319A (sh)
NO (2) NO321894B1 (sh)
NZ (2) NZ529118A (sh)
PA (1) PA8545701A1 (sh)
PE (1) PE20021064A1 (sh)
PL (1) PL367091A1 (sh)
PT (1) PT1390377E (sh)
SK (1) SK14402003A3 (sh)
TN (1) TNSN03121A1 (sh)
WO (1) WO2002094843A1 (sh)
YU (1) YU91603A (sh)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
IL143376A0 (en) * 1998-11-30 2002-04-21 Teva Pharma Ethanolate of azithromycin, process for the manufacture, and pharmaceutical compositions thereof
JP2004506664A (ja) * 2000-08-23 2004-03-04 ウォックハート・リミテッド 無水アジトロマイシンの製造法
KR100431431B1 (ko) * 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
JP2004530703A (ja) * 2001-05-22 2004-10-07 ファイザー・プロダクツ・インク 結晶形アジスロマイシン
ITMI20011762A1 (it) 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
AU2002348884A1 (en) 2001-12-21 2003-07-09 Pfizer Products Inc. Directly compressible formulations of azithromycin
JP2005515212A (ja) * 2001-12-21 2005-05-26 ファイザー・プロダクツ・インク アジスロマイシンの湿式造粒法
KR100676025B1 (ko) 2002-02-01 2007-01-29 화이자 프로덕츠 인코포레이티드 아지쓰로마이신의 건조 과립화 제제
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
CA2422972A1 (en) * 2003-03-21 2004-09-21 Apotex Inc. Isopropanolate of azithromycin and method of manufacturing
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1878432A1 (en) * 2003-07-24 2008-01-16 Pliva - Research and Development Ltd. Single dose fast dissolving azithromycin
US7572773B2 (en) 2003-07-24 2009-08-11 Pliva Hrvatska D.O.O. Single dose fast dissolving azithromycin
CA2678124C (en) * 2003-11-17 2014-10-07 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US20050250714A1 (en) * 2004-05-06 2005-11-10 Lin Kangwen L Crystalline forms of 9-(S)-erythromycylamine
WO2005118586A1 (en) * 2004-06-02 2005-12-15 Sandoz Ag Meropenem intermediate in crystalline form
US7683162B2 (en) 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
US8495244B2 (en) * 2005-06-29 2013-07-23 Jumpstart Wireless Corporation System and method for dynamic automatic communication path selection, distributed device synchronization and task delegation
EP1910393A2 (en) * 2005-07-05 2008-04-16 Hetero Drugs Limited A novel process for the preparation of didanosine using novel intermediates
WO2007007148A1 (en) * 2005-07-14 2007-01-18 Pfizer Products Inc. Process for forming amorphous azithromycin particles
US8188138B2 (en) * 2005-09-21 2012-05-29 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
BRPI0617947A2 (pt) * 2005-10-31 2011-08-09 Janssen Pharmaceutica Nv processos para a preparação de derivados de piperazinil e diazapanil benzamida
US8558765B2 (en) * 2005-11-07 2013-10-15 Global Oled Technology Llc Method and apparatus for uniformity and brightness correction in an electroluminescent display
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
CN101568544B (zh) * 2006-10-27 2016-10-26 西格诺药品有限公司 包含4‑[9‑(四氢‑呋喃‑3‑基)‑8‑(2,4,6‑三氟‑苯氨基)‑9h‑嘌呤‑2‑基氨基]‑环己烷‑1‑醇的固体形式,其组合物,及其用途
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
US7919676B2 (en) 2007-08-03 2011-04-05 Pioneer Hi-Bred International, Inc. Msca1 nucleotide sequences impacting plant male fertility and method of using same
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
US8216363B2 (en) * 2008-10-27 2012-07-10 Illinois Institute Of Technology Continuous antisolvent crystallization process and system using plug flow reactors
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
MX2011009548A (es) 2009-03-13 2011-12-14 Da Volterra Composiciones y metodos para la eliminacion de bacterias gram-negativas.
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
CN103189360A (zh) * 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的非吸湿性盐
CN103930419B (zh) * 2011-09-30 2016-06-01 广东东阳光药业有限公司 阿齐沙坦的晶型及其制备方法
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Pde10阻害剤の固体状態形態
JP2020533412A (ja) * 2017-09-07 2020-11-19 アセネックス エイチケイ イノベイティブ リミテッド 2−(5−(4−(2−モルホリノエトキシ)フェニル)ピリジン−2−イル)−n−ベンジルアセトアミドの固体形態
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43116B (en) 1979-04-02 1989-04-30 Pliva Pharm & Chem Works Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4465674A (en) 1983-09-06 1984-08-14 Pfizer Inc. Azahomoerythromycin D derivative and intermediates therefor
RO107257B1 (ro) * 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (en) 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US4983531A (en) * 1990-02-12 1991-01-08 Motorola, Inc. Method of fabricating a single polysilicon bipolar transistor which is compatible with a method of fabricating CMOS transistors
CN1034734C (zh) 1993-12-10 1997-04-30 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
CN1093370A (zh) * 1993-12-10 1994-10-12 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
EP0915899B1 (en) * 1996-07-29 2004-08-04 Abbott Laboratories Preparation of crystal form ii of clarithromycin
CN1161971A (zh) 1997-01-03 1997-10-15 石家庄制药集团有限公司 一种阿齐霉素结晶及其制备方法
PT102130A (pt) 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
TW546302B (en) 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CA2245398C (en) 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
IL143376A0 (en) * 1998-11-30 2002-04-21 Teva Pharma Ethanolate of azithromycin, process for the manufacture, and pharmaceutical compositions thereof
DE60044515D1 (de) * 1999-06-29 2010-07-15 Sandoz Ag Azithromycinmonohydrat
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
ATE388159T1 (de) 2000-01-04 2008-03-15 Teva Pharma Verfahren zur herstellung von azithromycin- dihydrat
ES2162764B1 (es) 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
WO2002007736A1 (en) 2000-07-24 2002-01-31 Cadila Pharmaceuticals Limited The process for manufacturing of clear liquid pharmaceutical composition of azithromycin
CA2417353C (en) 2000-07-25 2009-09-01 Laboratorio Silanes,S.A. De C.V. Single-step process for preparing 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle (11.2.1)hexadeca-1(2)-en-8-one, and obtaining a new form of 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin a
ES2172417B1 (es) 2000-07-31 2003-09-16 Sint Quimica Sa Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
ITBO20000471A1 (it) 2000-07-31 2002-01-31 Vieri Ridolfi Dispositivo di supporto per prodotti da fumo particolarmente sigarette .
AU2001214115A1 (en) 2000-08-01 2002-02-13 Habil F. Khorakiwala Process for the preparation of anhydrous azithromycin
JP2004506664A (ja) 2000-08-23 2004-03-04 ウォックハート・リミテッド 無水アジトロマイシンの製造法
HU229488B1 (hu) 2000-11-27 2014-01-28 Sandoz Ag Eljárás makrolid hidrátok elõállítására
IN190080B (sh) 2001-01-29 2003-06-07 Alembic Ltd
KR100431431B1 (ko) 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
JP2004530703A (ja) * 2001-05-22 2004-10-07 ファイザー・プロダクツ・インク 結晶形アジスロマイシン
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
WO2003032922A2 (en) 2001-10-18 2003-04-24 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions

Also Published As

Publication number Publication date
ES2258142T3 (es) 2006-08-16
US20040043945A1 (en) 2004-03-04
PA8545701A1 (es) 2003-09-05
US20050192234A1 (en) 2005-09-01
HUP0400446A2 (hu) 2004-09-28
KR20040014525A (ko) 2004-02-14
EP1390377A1 (en) 2004-02-25
MXPA03010028A (es) 2004-02-12
JP2007161726A (ja) 2007-06-28
NO321894B1 (no) 2006-07-17
JP4584162B2 (ja) 2010-11-17
CZ20033154A3 (en) 2004-04-14
US20050245469A1 (en) 2005-11-03
US7105179B2 (en) 2006-09-12
GEP20084399B (en) 2008-06-10
EA009611B1 (ru) 2008-02-28
US7282486B2 (en) 2007-10-16
US6977243B2 (en) 2005-12-20
US20030162730A1 (en) 2003-08-28
NZ529118A (en) 2005-10-28
NZ539801A (en) 2006-10-27
US7309782B2 (en) 2007-12-18
YU91603A (sh) 2006-08-17
ATE319730T1 (de) 2006-03-15
US20050256063A1 (en) 2005-11-17
BR0209918A (pt) 2004-03-30
EA200500630A1 (ru) 2006-02-24
PT1390377E (pt) 2006-06-30
DK1390377T3 (da) 2006-06-19
DE60209704D1 (de) 2006-05-04
DE60209704T2 (de) 2006-11-16
US7053192B2 (en) 2006-05-30
CA2391659A1 (en) 2002-11-22
EE200300575A (et) 2004-04-15
JP2006152002A (ja) 2006-06-15
JP2004530703A (ja) 2004-10-07
WO2002094843A1 (en) 2002-11-28
US7081525B2 (en) 2006-07-25
TNSN03121A1 (en) 2005-12-23
NO20035177D0 (no) 2003-11-21
MA27023A1 (fr) 2004-12-20
US20040043944A1 (en) 2004-03-04
US20040082527A1 (en) 2004-04-29
CR7159A (es) 2004-02-23
PL367091A1 (en) 2005-02-21
US20050256062A1 (en) 2005-11-17
DE60228345D1 (de) 2008-09-25
SK14402003A3 (sk) 2004-06-08
NO20061049L (no) 2003-05-12
EA007618B1 (ru) 2006-12-29
MY129319A (en) 2007-03-30
US20050090459A1 (en) 2005-04-28
PE20021064A1 (es) 2002-11-21
US7307156B2 (en) 2007-12-11
ATE404575T1 (de) 2008-08-15
AP2003002906A0 (en) 2003-12-31
IL158591A0 (en) 2004-05-12
EA200301115A1 (ru) 2004-04-29
EP1390377B1 (en) 2006-03-08
ES2310886T3 (es) 2009-01-16
CA2391659C (en) 2006-05-30
AU2002256846B2 (en) 2007-04-05
KR100574153B1 (ko) 2006-04-25
IS7007A (is) 2003-10-30
US20040138149A1 (en) 2004-07-15
AR036022A1 (es) 2004-08-04

Similar Documents

Publication Publication Date Title
BG108370A (bg) Кристални форми на азитромицин
AU2002256846A1 (en) Crystal Forms of Azithromycin
US6727352B2 (en) Methods of making macrolides
ZA200308341B (en) Crystal Forms of Azithromycin.
US6258785B1 (en) Crystalline 9-E-(O-methyl)oxime of 11, 12-dideoxy-3-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyloxy)-6-O-methyl-12,11-(iminocarbonyl-(2-(3-(4-(3-pyridinyl)1H-imadazol-1-yl)propyl)hydrazono))-3-oxoerythromycin
EP1671979B1 (en) New Cristal Form of Azithromycin
CA2536914C (en) Crystal forms of azithromycin